Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ACADEMIA
NCC Launches Investigator-Led Studies on 5 Unapproved, Off-Label Drugs for Pediatric, AYA Cancers
The National Cancer Center (NCC) said on January 19 that it has kicked off investigator-initiated studies earlier this month for six unapproved or off-label medicines including five from Novartis, targeting pediatric and AYA (adolescent and young adult) cancers. The studies…
To read the full story
Related Article
- NCC to Add Cabozantinib, Valemetostat to Pediatric, AYA Cancer Trial
February 27, 2024
ACADEMIA
- Cancer Drug Supply Risks Spur Calls for Pricing Reform: JSMO
March 31, 2026
- Japan Ophthalmology Society Flags Off-Label Concerns Ahead of Upneeq Launch
March 30, 2026
- Real-World Study Backs Lecanemab Safety, 90% Stay on Treatment
March 25, 2026
- CAR-T Reimbursement Insufficient, Kyoto University Hospital Chief Warns
March 11, 2026
- Japan Begins Investigator-Led PII of Padcev in Small Bowel Adenocarcinoma
March 3, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…